4D Molecular Therapeutics, Inc.

FDMT

Held by 4 specialist biotech funds

High Convergence

Share on X

Fund Holdings

4 fund convergence

Baker Bros. Advisors RA Capital Management RTW Investments

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management9.9%Feb 17, 2026

SC 13G/ARA Capital Management9.9%Feb 14, 2025

SC 13G/A

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 475,737Value: $3.6M

## Signal Note: Baker Bros. Initiates Position in FDMT Baker Bros. taking a new, highly concentrated position in 4D Molecular Therapeutics is a significant signal given their track record of high-conviction bets in gene therapy — FDMT's lead asset is intravitreal AAV vector 4D-150 for wet AMD/diabetic macular edema, currently in a pivotal Phase 3 PRISM trial with topline data expected in 2025, positioning this as a catalyst-driven entry. **Note: The reported position value of ~$3.57B appears anomalous relative to FDMT's current market cap (~$300-500M range) and likely reflects a data/filing error — the share count of ~476K shares would value closer to ~$3.5-7M at recent prices, which is more consistent but still notable as a new position from a fund that runs

RA Capital ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

IRON4 funds SYRE3 funds TSHA3 funds IMCR3 funds JBIO3 funds KYMR3 funds STOK3 funds GPCR

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: RA Capital Initiates $42.4M Position in 4D Molecular Therapeutics** RA Capital's new 5.6M share stake signals conviction in 4D's gene therapy platform, particularly for inherited retinal diseases (IRDs) where the company is advancing multiple AAV programs including 4D-150 in X-linked retinitis pigmentosa. The timing likely reflects anticipated near-term clinical readouts or regulatory milestones that could validate 4D's manufacturing scalability and biodistribution approach—key de-risking events for ocular gene therapy given prior manufacturing constraints in the space.